Roger J. Hill PhD MBA is the Executive Director, Global Business Development & Licensing at Boehringer Ingelheim Pharmaceutical Company. The pharmaceutical company Boehringer Ingelheim was founded in 1885 by Albert Boehringer (1861-1939) in Ingelheim, Germany. From its beginnings in 1885 when it employed just 28 people, the company has since become a global privately held enterprise. As part of research and development activities for innovative drugs, the company focuses primarily on the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. Prescription Medicines, which represents the bulk of Boehringer Ingelheim’s Human Pharmaceuticals business, accounts for 79 % of its total net sales and generated in 2009 10,058 million euro. Hill, a native of Dublin, previously held top positions at Pfizer and Sterling Winthrop. He received a Bachelor's and Ph.D in Pharmacy from UCD, and an MBA in entrepreneurial finance from Northeastern in Boston. A future aspiration of Hill's is to transition to an executive level position at an emerging innovative life sciences company. Hill and his wife Leslie have two sons.
Return to Life Science 50